Literature DB >> 29481487

Positive or Not, That Is the Question: HIV Testing for Individuals on Pre-exposure Prophylaxis.

Jason Zucker1,2, Caroline Carnevale3, Alex J Rai4, Peter Gordon1, Magdalena E Sobieszczyk1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29481487      PMCID： PMC5953799          DOI： 10.1097/QAI.0000000000001665

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  11 in total

1.  Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

Authors:  David C Knox; Peter L Anderson; P Richard Harrigan; Darrell H S Tan
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

2.  Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.

Authors:  Elske Hoornenborg; Maria Prins; Roel C A Achterbergh; Lycke R Woittiez; Marion Cornelissen; Suzanne Jurriaans; Neeltje A Kootstra; Peter L Anderson; Peter Reiss; Henry J C de Vries; Jan M Prins; Godelieve J de Bree
Journal:  Lancet HIV       Date:  2017-09-14       Impact factor: 12.767

3.  Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.

Authors:  Mariya V Sivay; Maoji Li; Estelle Piwowar-Manning; Yinfeng Zhang; Sarah E Hudelson; Mark A Marzinke; Rivet K Amico; Andrew Redd; Craig W Hendrix; Peter L Anderson; Kevin Bokoch; Linda-Gail Bekker; Frits van Griensven; Sharon Mannheimer; James P Hughes; Robert Grant; Susan H Eshleman
Journal:  J Acquir Immune Defic Syndr       Date:  2017-07-01       Impact factor: 3.731

4.  A signal-to-cutoff ratio in the Abbott architect HIV Ag/Ab Combo assay that predicts subsequent confirmation of HIV-1 infection in a low-prevalence setting.

Authors:  Tomas Ostergaard Jensen; Peter Robertson; Ross Whybin; Ian Chambers; Monica Lahra; William Rawlinson; Jeffrey John Post
Journal:  J Clin Microbiol       Date:  2015-02-11       Impact factor: 5.948

Review 5.  Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure.

Authors:  M P Busch; G A Satten
Journal:  Am J Med       Date:  1997-05-19       Impact factor: 4.965

6.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

Authors:  Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

7.  Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.

Authors:  Martin Markowitz; Howard Grossman; Peter L Anderson; Robert Grant; Monica Gandhi; Howard Horng; Hiroshi Mohri
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-01       Impact factor: 3.731

8.  Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology.

Authors:  Mark S de Souza; Suteeraporn Pinyakorn; Siriwat Akapirat; Supanit Pattanachaiwit; James L K Fletcher; Nitiya Chomchey; Eugene D Kroon; Sasiwimol Ubolyam; Nelson L Michael; Merlin L Robb; Praphan Phanuphak; Jerome H Kim; Nittaya Phanuphak; Jintanat Ananworanich
Journal:  Clin Infect Dis       Date:  2016-06-17       Impact factor: 9.079

9.  The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.

Authors:  Deborah Donnell; Eric Ramos; Connie Celum; Jared Baeten; Joan Dragavon; Jordan Tappero; Jairam R Lingappa; Allan Ronald; Kenneth Fife; Robert W Coombs
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

10.  HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART.

Authors:  Jintanat Ananworanich; Nicolas Chomont; Leigh Ann Eller; Eugene Kroon; Sodsai Tovanabutra; Meera Bose; Martin Nau; James L K Fletcher; Somporn Tipsuk; Claire Vandergeeten; Robert J O'Connell; Suteeraporn Pinyakorn; Nelson Michael; Nittaya Phanuphak; Merlin L Robb
Journal:  EBioMedicine       Date:  2016-07-20       Impact factor: 8.143
View more
  5 in total

1.  Am I Positive? Improving Human Immunodeficiency Virus Testing in the Era of Preexposure Prophylaxis and Immediate Antiretroviral Therapy Using Machine Learning.

Authors:  Jason Zucker; Caroline Carnevale; Peter Gordon; Magdalena E Sobieszczyk; Alex J Rai
Journal:  Open Forum Infect Dis       Date:  2022-05-18       Impact factor: 4.423

Review 2.  Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies.

Authors:  Sarah E Rutstein; Dawn K Smith; Shona Dalal; Rachel C Baggaley; Myron S Cohen
Journal:  Lancet HIV       Date:  2020-08-27       Impact factor: 12.767

3.  Pattern and Frequency of Seroreactivity to Routinely Used Serologic Tests in Early-Treated Infants With HIV.

Authors:  Thanyawee Puthanakit; Jintanat Ananworanich; Siriwat Akapirat; Supanit Pattanachaiwit; Sasiwimol Ubolyam; Vatcharain Assawadarachai; Panadda Sawangsinth; Thidarat Jupimai; Suvaporn Anugulruengkitt; Monta Tawan; Pope Kosalaraksa; Thitiporn Borkird; Piyarat Suntarattiwong; Suparat Kanjanavanit; Mark S de Souza
Journal:  J Acquir Immune Defic Syndr       Date:  2020-03-01       Impact factor: 3.771

Review 4.  Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review.

Authors:  Tamara Elliott; Eduard J Sanders; Meg Doherty; Thumbi Ndung'u; Myron Cohen; Pragna Patel; Gus Cairns; Sarah E Rutstein; Jintanat Ananworanich; Colin Brown; Sarah Fidler
Journal:  J Int AIDS Soc       Date:  2019-12       Impact factor: 5.396

Review 5.  The current landscape of pre-exposure prophylaxis service delivery models for HIV prevention: a scoping review.

Authors:  Jef Vanhamel; Anke Rotsaert; Thijs Reyniers; Christiana Nöstlinger; Marie Laga; Ella Van Landeghem; Bea Vuylsteke
Journal:  BMC Health Serv Res       Date:  2020-07-31       Impact factor: 2.655
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.